Nifedipine: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Nifedipine. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Giddiness | 27% |
| Flushing, heat sensation | 25% |
| Headache | 15.8% |
| Weakness | 12% |
| Nausea, heartburn | 11% |
| Muscle cramps, tremor | 8% |
| Nasal congestion, sore throat | 8% |
| Peripheral edema | 7% |
| Nervousness, mood changes | 7% |
| Palpitations | 7% |
| Dyspnea, cough, wheezing | 6% |
| Fatigue | 5.9% |
| Dizziness | 4.5% |
| Constipation | 3.3% |
| Nausea | 3.3% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
I. Vasospastic Angina Nifedipine Extended-Release Tablets, USP are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-Release Tablets, USP may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-Release Tablets, USP are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in…
Medical disclaimer: Always consult a qualified healthcare professional about any medication.